All Releases
 |
OSI Pharmaceuticals Board of Directors to Review Astellas' Unsolicited Tender Offer
Mar 2, 2010
|
9.4 KB |
| |
MELVILLE, N.Y., Mar 02, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) ("OSI") today confirmed that
Astellas Pharma Inc. ("Astellas") has commenced an unsolicited tender
offer to acquire all outstanding common shares of OSI for $52.00 per
share in cash.
Consistent with its fiduciary duties and as required ...
|
|
OSI Pharmaceuticals Confirms Receipt of Unsolicited Proposal From Astellas Pharma
Mar 1, 2010
|
9.8 KB |
| |
MELVILLE, N.Y., Mar 01, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today confirmed that it has
received an unsolicited proposal from Astellas Pharma Inc. ("Astellas")
to acquire the Company for $52.00 per share.
OSI's Board of Directors will review the proposal with its financial and
legal advisors. OS...
|
|
OSI Pharmaceuticals to Present at the RBC Capital Markets Healthcare Conference on Tuesday, March 2, 2010
Feb 25, 2010
|
8.1 KB |
| |
MELVILLE, N.Y., Feb 25, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that OSI
Management will present at the RBC Capital Healthcare Conference in New
York, NY on Tuesday, March 2nd at 2:30pm (Eastern Time) and
will provide an overview on the Company's product portfolio and business
...
|
|
OSI Pharmaceuticals, Inc. Announces Year End 2009 Financial Results
Feb 23, 2010
|
28.3 KB |
| |
MELVILLE, N.Y., Feb 23, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today its financial
results for the year ended December 31, 2009. The Company reported total
revenues from continuing operations of $428 million for 2009 compared to
revenues of $379 million for 2008, a 13% increase over the pr...
|
|
OSI Pharmaceuticals to Announce Fourth Quarter and Year-End 2009 Financial Results on February 23, 2010
Feb 9, 2010
|
8.7 KB |
| |
MELVILLE, N.Y., Feb 09, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that its fourth
quarter and year-end 2009 financial results will be released on February
23, 2010, after the markets close. Following the announcement, OSI's
management will host a live conference call and webcast at 5:00...
|
|
Novella Clinical and OSI Pharmaceuticals Expand Clinical Services Agreement
Jan 28, 2010
|
11.8 KB |
| |
RESEARCH TRIANGLE PARK, N.C. & MELVILLE, N.Y., Jan 28, 2010 (BUSINESS WIRE) -- Novella Clinical Inc. (formerly PharmaLinkFHI) and OSI Pharmaceuticals,
Inc. (NASDAQ: OSIP) announced today that the Companies will expand their
existing clinical service agreement. Under the terms of the new
agreement, effective February 1, 2010,...
|
|
FDA Extends Review Period for Tarceva Application for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer
Jan 15, 2010
|
13.4 KB |
| |
MELVILLE, N.Y. & SOUTH SAN FRANCISCO, Calif., Jan 15, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc., a wholly
owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced
today that the U.S. Food and Drug Administration (FDA) has extended the
review period for the supplementa...
|
|
OSI Pharmaceuticals, Inc. Announces Fourth Quarter and 2009 Full Year Tarceva Sales at JP Morgan Healthcare Conference
Jan 12, 2010
|
8.9 KB |
| |
MELVILLE, N.Y., Jan 12, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) will present fourth quarter and
year end Tarceva(R) (erlotinib) sales today during the
Company's presentation at the 28th Annual JP Morgan
Healthcare Conference in San Francisco, CA. For the three months ended
December 31, 2009, ...
|
|
OSI Pharmaceuticals to Present at the 28th Annual JP Morgan Healthcare Conference on Tuesday, January 12, 2010
Jan 6, 2010
|
8.1 KB |
| |
MELVILLE, N.Y., Jan 06, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that OSI
Management will present at the JP Morgan Healthcare Conference in San
Francisco, CA on Tuesday, January 12th at 3:00pm (Pacific
Time) and will provide an overview on the Company's product portfolio
and bu...
|
|
U.S. Patent and Trademark Office Grants Reissued Patent Replacing OSI Pharmaceuticals' Tarceva(R) Composition of Matter Patent
Dec 29, 2009
|
8.8 KB |
| |
MELVILLE, N.Y., Dec 29, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today announced that the U.S.
Patent & Trademark Office (PTO) has granted reissue patent RE41,065,
replacing Tarceva's(R) (erlotinib) composition of matter patent
(formerly No.5,747,498). The Company had applied for the reissue patent
...
|
|
OSI Pharmaceuticals Updates Preliminary Revenue & Re-affirms Adjusted Earnings Growth Rate Guidance for 2010
Dec 22, 2009
|
11.1 KB |
| |
MELVILLE, N.Y., Dec 22, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today provided an update to the
preliminary revenue and adjusted earnings per share growth rate guidance
provided to investors at the Company's recent analyst R&D day meeting on
December 3, 2009. The Company now believes that the 2010 ov...
|
|
OSI Pharmaceuticals Announces Conference Call on ODAC Review of Tarceva(R) for Use as First-line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
Dec 16, 2009
|
9.5 KB |
| |
MELVILLE, N.Y., Dec 16, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) announced today that the Company
will host a live conference call Thursday, December 17, at 8:30 AM
Eastern Time to discuss the Oncologic Drug Advisory Committee (ODAC)
panel's review of the supplemental New Drug Application (sNDA) for us...
|
|
FDA Advisory Committee Recommends Against Approving Tarceva for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer
Dec 16, 2009
|
15.8 KB |
| |
GAITHERSBURG, Md., Dec 16, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc., a wholly
owned member of the Roche Group (SIX: RO, ROG)(OTCQX: RHHBY), announced
today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs
Advisory Committee (ODAC) voted 12 to one recommending agains...
|
|
OSI Pharmaceuticals to Webcast its R&D Analyst Day on Thursday, December 3rd
Nov 19, 2009
|
9.1 KB |
| |
MELVILLE, N.Y., Nov 19, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that it will
host a live webcast of its R&D Analyst Day on Thursday, December 3, 2009
at 12:30 p.m. Eastern Time. The webcast will be hosted by Colin Goddard,
Ph.D., Chief Executive Officer, and members of OSI's managemen...
|
|
OSI Pharmaceuticals Announces Tarceva to Be Reviewed by the FDA's Oncologic Drugs Advisory Committee for Use as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
Nov 16, 2009
|
11.8 KB |
| |
MELVILLE, N.Y., Nov 16, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the
Oncologic Drugs Advisory Committee (ODAC) will review the use of Tarceva(R)
(erlotinib) as a first-line maintenance therapy for patients with
advanced non-small cell lung cancer (NSCLC) who have not progressed
...
|
|
OSI Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009
Nov 9, 2009
|
8.8 KB |
| |
MELVILLE, N.Y., Nov 09, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that OSI
Management will present at the Lazard Healthcare Conference in New York,
NY on Tuesday, November 17, 2009 at 8:55am (Eastern Time) and will
provide an overview on the Company's product portfolio and business
...
|
|
OSI Pharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare Conference on Tuesday, November 3, 2009
Oct 27, 2009
|
8.5 KB |
| |
MELVILLE, N.Y., Oct 27, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that OSI
Management will present at the Oppenheimer Healthcare Conference in New
York, NY on Tuesday, November 3, 2009 at 3:20pm (Eastern Time) and will
provide an overview on the Company's product portfolio and business ...
|
|
OSI Pharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
Oct 21, 2009
|
26.7 KB |
| |
MELVILLE, N.Y., Oct 21, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today its financial
results for the Company's third quarter ended September 30, 2009. The
Company reported total revenues from continuing operations of $111
million for the third quarter of 2009 compared to revenues of $95
...
|
|
OSI Pharmaceuticals to Announce Third Quarter 2009 Financial Results on October 21, 2009
Oct 12, 2009
|
9.2 KB |
| |
MELVILLE, N.Y., Oct 12, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that its third
quarter 2009 financial results will be released on October 21, 2009,
after the markets close. Following the announcement, OSI's management
will host a live conference call and webcast at 5:00p.m. Eastern Ti...
|
|
U.S. Patent and Trademark Office Issues a Notice of Allowance in OSI Pharmaceuticals' Reissue Application on Tarceva(R) Composition of Matter Patent
Sep 17, 2009
|
12.1 KB |
| |
MELVILLE, N.Y., Sep 17, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the U.S.
Patent & Trademark Office has issued a "Notice of Allowance" in OSI's
reissue application for U.S. Patent No.5,747,498 (the '498) composition
of matter patent for Tarceva(R) (erlotinib). The reissued
...
|
|
|
0.55 (0.95%)